review
devot
problem
creat
new
antivir
drug
base
glycyrrhiz
acid
ga
major
triterpen
glycosid
extract
root
common
ural
licoric
glycyrrhiza
glabra
l
g
uralensi
fisher
respect
publish
data
natur
ga
sourc
antivir
activ
ga
deriv
clinic
applic
gabas
drug
properti
gacontain
biolog
activ
nutrient
addit
summar
possibl
mechan
antivir
activ
ga
deriv
examin
shown
chemic
modif
ga
promis
way
design
new
highli
activ
antivir
drug
prophylaxi
treatment
hiv
hepat
b
c
coronaviru
herp
simplex
viru
infect
arsen
effect
antivir
prepar
etiotrop
andor
immunocorrect
effect
approv
medic
use
present
limit
divid
three
main
group
accord
chemic
composit
mechan
action
spectrum
activ
durat
clinic
effect
includ
inhibitor
viral
enzym
interferon
inductor
immunomodul
thu
mainli
revers
transcriptas
rt
hiv
proteas
inhibitor
use
treat
hiv
infect
affect
biosynthesi
viral
protein
revers
transcript
viru
replic
cycl
therebi
suppress
hiv
multipl
hiv
rt
inhibitor
wide
use
class
antiretrovir
prepar
world
prepar
hiv
rt
inhibitor
current
approv
treatment
hiv
infect
class
antihiv
prepar
repres
three
subclass
compound
ie
nucleosid
hiv
rt
inhibitor
nonnucleosid
nucleotid
hiv
rt
inhibitor
first
subclass
includ
zidovudin
azidothymidin
first
antihiv
agent
began
use
didanosin
stavudin
lamivudin
zalcitabin
abacavir
other
prepar
nucleosid
analog
mimic
one
four
natur
rt
substrat
action
prepar
base
inhibit
rt
hiv
polymeras
respons
copi
hiv
rna
dna
provir
dna
integr
dna
hostcel
second
group
hiv
rt
inhibitor
typifi
three
prepar
nevirapin
delavaridin
efavirenz
effect
rt
inhibitor
inact
rt
nucleotid
inhibitor
hiv
rt
second
gener
prepar
approv
medic
use
group
includ
tenofovir
use
prodrug
tenofovir
disoproxil
fumar
hiv
proteas
inhibitor
approv
hivinfect
therapi
ritonavir
indinavir
nelfinavir
saquinavir
amprenavir
etc
princip
drawback
hiv
rt
inhibitor
high
toxic
produc
undesir
side
effect
half
patient
myopathi
neuropathi
pancreat
gi
tract
upset
etc
modern
effect
antivir
therapi
hiv
infect
combin
therapi
includ
simultan
rt
inhibitor
complex
hiv
proteas
inhibitor
shown
combin
therapi
reduc
viral
load
allow
level
patient
lethal
improv
qualiti
life
patient
incorpor
prepar
activ
stage
viru
penetr
cell
recent
becom
new
approach
treat
hiv
infect
new
class
antiretrovir
agent
fusion
inhibitor
act
directli
protein
hiv
molecul
locat
viru
surfac
chang
form
viru
order
facilit
penetr
host
cell
group
includ
prepar
enfuvirtid
synthet
polypeptid
consist
amino
acid
princip
problem
therapi
rt
inhibitor
develop
resist
prepar
prolong
therapi
rt
hiv
proteas
inhibitor
gener
mutant
strain
viru
thu
hiv
becom
resist
prepar
zidovudin
stavudin
hiv
proteas
inhibitor
within
sever
month
resist
due
mutat
occur
bind
site
receptor
lead
loss
effect
antihiv
prepar
treatment
therefor
compound
mechan
action
relat
initi
stage
viru
replic
cycl
attract
inhibitor
viru
multipl
cycl
directli
affect
code
transmiss
genet
inform
interferon
last
year
base
prepar
treat
viral
hepatitis
b
c
analog
nucleosid
block
synthesi
viral
dna
rna
replac
natur
nucleosid
exampl
lamivudin
acyclovir
ribavirin
prodrug
form
viramidin
rebetol
sorivudin
entecavir
vidavirin
etc
use
monotherapi
interferon
inadequ
acycl
nucleosid
phosphon
adefovir
tenofovir
prodrug
form
exhibit
high
antivir
activ
viral
hepat
b
effect
antivir
therapi
increas
combin
therapi
lamivudin
interferon
patient
chronic
hepat
b
ribavirin
ainterferon
chronic
hepat
c
new
approach
monotherapi
combin
therapi
new
gener
antivir
agent
new
mechan
action
natur
compound
obtain
avail
plant
materi
modifi
analog
deserv
special
attent
develop
last
year
method
ration
drug
design
combinatori
chemistri
creation
librari
compound
addit
optim
structur
lead
natur
compound
synthesi
analog
given
bioactiv
signific
effect
program
develop
drug
natur
origin
sever
promin
pharmaceut
compani
greater
antitumor
antiinfect
prepar
present
known
world
base
natur
compound
plant
origin
glycyrrhiz
acid
ga
main
saponin
licoric
root
glycyrrhiza
glabra
l
g
uralensi
fisher
leguminosa
bean
extract
natur
compound
great
valu
medicin
basi
creat
new
highli
effect
prepar
treat
prevent
viral
infect
immunodeficit
variou
etiolog
speci
variou
licoric
grow
eurasia
known
genu
glycyrrhiza
l
divid
two
section
accord
anatom
morpholog
chemic
triterpen
composit
featur
true
fals
licoric
euglycyrrhiza
boiss
pseudoglycyrrhiza
regel
krug
true
licoric
includ
six
speci
g
glabra
linn
var
typica
g
uralensi
fisher
g
korshinski
grig
g
inflata
batalin
g
aspera
pall
g
glandtilifera
waldst
et
w
g
taxissima
vass
offici
medicin
raw
materi
subterrean
organ
root
rhizom
g
glabra
g
uralensi
distribut
g
glabra
expans
encompass
territori
southern
europ
northwest
china
includ
spain
itali
russia
ukrain
volga
region
northern
caucas
western
siberia
azerbaidzhan
turkmenistan
kazakhstan
kyrgyzstan
afghanistan
turkey
mongolia
syria
iraq
iran
countri
near
middl
east
plant
grow
well
salin
soil
long
root
penetr
depth
usual
reach
groundwat
level
largest
stand
g
glabra
locat
valley
river
amudarja
syrdarja
ural
g
uralensi
distribut
primarili
southern
ural
northern
central
eastern
region
kazakhstan
uzbekistan
kyrgyzstan
south
western
central
eastern
siberia
mongolia
northeastern
china
turkey
spain
greec
iraq
western
siberian
stepp
northernmost
region
g
uralensi
grow
raw
materi
base
licoric
root
ci
last
decad
stand
valley
amudarja
syrdarja
river
broad
distribut
consist
licoric
make
plant
favor
subject
cultiv
ensur
reliabl
raw
materi
base
g
glabra
g
uralensi
cultiv
salin
soil
licoric
plantat
establish
uzbekistan
turkmenistan
kazakhstan
mongolia
root
g
uralensi
year
old
plantat
suitabl
raw
materi
possibl
substitut
two
offici
speci
true
licoric
g
aspera
pall
grow
dagestan
east
caucas
syrdarja
river
basin
eastern
balkhash
mongolia
chines
jungaria
g
korshinski
grig
grow
southern
central
ural
howev
g
korshinski
rare
speci
appear
russian
red
book
root
g
glabra
licoric
licoric
root
radix
glycyrrhiza
seu
radix
liquiritia
one
valuabl
medicin
industri
plant
licoric
root
medicin
plant
approv
use
medicin
includ
edit
ussr
state
pharmacopoeia
pharmacopoeia
industri
develop
countri
world
two
type
raw
materi
use
medicin
purpos
crude
root
radix
glycyrrhiza
naturali
clean
root
radix
glycyrrhiza
mundata
licoric
root
process
product
use
variou
industri
sector
includ
pharmaceut
food
tobacco
cosmet
chemic
paper
patent
relat
plant
raw
materi
demand
licoric
root
global
economi
domest
constantli
increas
reserv
licoric
russian
feder
insuffici
estim
howev
exist
data
suggest
intern
requir
rf
met
raw
materi
harvest
licoric
root
bottom
volga
ural
river
siberia
altai
medicin
valu
licoric
root
determin
uniqu
broad
array
biolog
activ
compound
refer
primarili
triterpen
glycosid
triterpenoid
phenol
compound
structur
type
oand
cglycosid
licoric
root
contain
also
organ
acid
glucos
saccharos
polysaccharid
mannit
starch
steroid
asparagin
protein
gum
ascorb
acid
essenti
oil
pectin
substanc
miner
salt
etc
rf
pharmaceut
industri
produc
licoric
root
thick
dri
extract
syrup
licoric
root
syrup
licoric
syrup
chest
elixir
glycyram
liquiriton
flacarbin
prepar
phosphogliv
powder
licoric
root
complex
etc
chest
elixir
licoric
root
syrup
use
expector
diseas
respiratori
tract
thick
dri
extract
excipi
variou
drug
glycyram
monoammonium
salt
glycyrrhiz
acid
prepar
antiinflammatori
action
use
bronchial
asthma
allerg
dermat
eczema
liquiriton
flacarbin
prepar
indic
treat
hyperacid
gastriti
stomach
ulcer
prepar
g
uralensi
use
analog
g
glabra
research
chemistri
technolog
pharmacolog
basic
group
biolog
activ
compound
licoric
review
describ
monograph
use
licoric
global
practic
also
review
alreadi
note
princip
bioactiv
compon
licoric
root
extract
triterpen
glycosid
occur
root
mix
potassiumcalcium
salt
glycyrrizin
impart
root
sugarysweet
tast
molecul
construct
triterpen
aglycon
sapogenin
glycyrrhetin
acid
ii
pentacycl
bamyrintyp
triterpenoid
two
molecul
dglucuron
acid
dglcu
bond
aglycon
obglycosid
bond
configur
anomer
center
glycosid
carbon
chain
found
analyz
c
nmr
pmr
spectra
bconfigur
glycosid
bond
dglucuron
acid
bond
aglycon
establish
princip
metabolit
ie
ii
comprehens
studi
triterpenoid
isol
root
g
glabra
g
uralensi
g
korshinski
compound
ii
boleanenictyp
triterpen
ketoacid
structur
acid
ii
literatur
chemistri
biolog
activ
ii
examin
detail
monograph
review
offici
sourc
root
rhizom
g
glabra
g
uralensi
compound
wild
g
glabra
vari
depend
mani
factor
humid
salt
composit
salin
mechan
soil
composit
season
develop
etc
habitat
also
import
effect
accumul
valuabl
compound
licoric
root
optim
time
collect
root
consid
second
half
spring
content
second
half
summer
autumn
root
g
uralensi
year
old
plantat
also
suitabl
raw
materi
requir
licoric
root
medicin
raw
materi
given
ussr
state
pharmacopoeia
content
g
korshinski
g
aspera
also
somewhat
import
sourc
addit
g
glabra
g
uralensi
highest
content
time
greater
g
glabra
observ
root
g
korshinski
root
rhizom
g
aspera
contain
ga
extract
licoric
compon
exhibit
antivir
activ
extract
g
glabra
inhibit
epsteinbarr
vi
virusolog
biochem
indic
improv
significantli
patient
chronic
hepat
c
treatment
g
glabra
tradit
chines
medicin
extract
g
glabra
root
exhibit
antivir
activ
japanes
enceph
viru
report
compon
licoric
activ
dormant
form
herp
viru
syrup
licoric
root
use
success
treat
herpet
stomat
children
antivir
activ
deriv
subject
heighten
attent
virusologist
clinician
last
decad
compound
monoammonium
salt
glycyram
inhibit
complet
vitro
reproduct
sever
dnaand
rnavirus
vaccinia
newcastl
vesicular
stomatitu
herp
simplex
herp
b
varicella
zoster
note
potent
inhibitor
herp
simplex
viru
type
compound
also
increas
resist
mice
thermal
edema
opportunist
herpet
infect
compound
effect
two
new
human
herp
virus
also
effect
human
cytomegaloviru
hepat
b
c
virus
hav
hbv
hcv
purifi
monoammonium
salt
inhibit
japanes
enceph
viru
purifi
activ
antivir
agent
licoric
recent
report
inhibit
ebv
viru
vitro
caus
lymphoma
carcinoma
furthermor
first
compound
effect
inhibit
replic
new
corona
virus
caus
sever
acut
respiratori
syndrom
sar
cov
report
end
deriv
could
inhibit
reproduct
hiv
caus
sensat
compound
concentr
mgml
inhibit
complet
cell
cultur
compound
today
princip
natur
compound
suitabl
therapi
hivinfect
patient
inhibit
reproduct
upon
oral
iv
administr
preliminari
clinic
studi
show
number
increas
viru
antigen
content
decreas
upon
administr
aid
patient
dose
mgd
indic
effect
vivo
inhibitor
combin
azidothymidin
prepar
exhibit
synerg
aid
therapi
one
main
drawback
azidothymidin
low
effect
block
reproduct
hiv
monocytesmacrophag
furthermor
produc
resist
mutant
form
viru
contrast
azidothymidin
deriv
activ
concentr
nontox
cell
shown
simultan
administr
azidothymidin
aid
patient
reduc
side
effect
latter
contrast
azidothymidin
prepar
suppress
effect
larg
extent
hiv
reproduct
thelper
cultur
monocyt
cell
report
complex
phenol
compon
licoric
root
could
produc
licochalcon
isolicoflavanol
glycocoumarin
suppress
hiv
prolifer
monosodium
monoammonium
salt
inhibit
also
reproduct
cell
cultur
thu
monoammonium
salt
glycyram
concentr
mgml
exhibit
pronounc
inhibit
reproduct
cell
cultur
index
select
ratio
prepar
concentr
caus
reduct
cell
vital
concentr
caus
reduct
hiv
reproduct
greater
indic
use
prepar
promis
treat
hivinfect
patient
compound
possess
pronounc
antivir
activ
virus
monosodium
salt
exhibit
antihiv
effect
chronic
infect
cell
cultur
stereoisom
iii
test
clinic
china
agent
treat
hepatitis
show
greater
activ
reduc
alanineand
aspartataminotransferas
sever
chemic
modifi
deriv
exhibit
pronounc
inhibit
reproduct
vitro
thu
pentasulf
salt
concentr
mgml
suppress
complet
reproduct
vitro
antivir
effect
compound
also
inhibit
hiv
rt
greater
pentasulf
inhibit
also
chronic
infect
model
sodium
salt
l
baltina
sulfat
variou
ester
iv
vi
prepar
antihiv
activ
time
greater
cell
cultur
na
k
nh
salt
possess
high
antivir
activ
propos
treat
viral
diseas
includ
aid
analog
vii
heteroannular
dien
system
aglycon
retain
antihiv
activ
cell
cultur
protect
effect
concentr
mm
glycosid
also
inhibit
viru
ic
mm
effect
ic
mm
sever
glycopeptid
addit
deriv
exhibit
cell
cultur
greater
antihiv
activ
glycopeptid
contain
three
sbzlci
moiti
inhibit
concentr
mgkg
accumul
virusspecif
protein
analog
azidothymidin
greater
antivir
activ
deriv
time
less
toxic
hivinfect
cell
azidothymidin
amid
prepar
inhibit
highli
effect
accumul
total
viru
antigen
reduc
activ
rt
chemotherapeut
index
compound
variou
paramet
much
greater
introduct
amino
acid
structur
ii
also
increas
substanti
activ
conjug
ga
bdgalactopyranosylamin
viii
ix
inhibit
concentr
mgml
accumul
cell
cultur
synthsiz
chemotherapeut
index
studi
deriv
reach
much
greater
semisynthet
deriv
nicotin
acid
call
niglizin
patent
hiv
inhibitor
antivir
activ
consider
greater
azidothymidin
chronic
infect
model
niglizin
highli
activ
inhibitor
wild
mutant
form
rt
niglizin
exhibit
synerg
combin
azidothymidin
ratio
azidothymidineresist
hiv
mutant
combin
nevirapin
well
known
nonnucleosid
inhibitor
rt
inhibit
rt
mechan
synerg
azidothymidin
niglizin
observ
cell
cultur
due
interact
two
compound
differ
function
region
rt
niglizin
exhibit
synerg
inhibit
rt
also
combin
nevirapin
argu
favor
mechan
antihiv
activ
niglizin
involv
rt
blockag
niglizin
therapeut
dose
affect
function
state
cardiovascular
hematopoiet
system
liver
kidney
function
induc
patholog
chang
brain
heart
lung
kidney
spleen
stomach
intestin
exhibit
teratogen
cancerogen
properti
prepar
interest
new
antivir
agent
set
properti
valuabl
medicin
niglizin
interest
prepar
effect
inductor
ginterferon
substanti
enhanc
therapeut
potenti
treat
hiv
infect
compound
combin
antivir
activ
hepatoprotect
antiinflammatori
antiulc
activ
practic
nontox
produc
avail
natur
compound
industri
method
prepar
drug
substanc
develop
prepar
suitabl
oral
administr
offer
tablet
g
niglizin
use
success
complex
therapi
patient
hemorrhag
fever
renal
syndrom
compound
deriv
glycyram
niglizin
form
first
group
compound
inhibit
highli
effect
reproduct
marburg
viru
caus
acut
hemorrhag
fever
peopl
high
level
lethal
amid
conjug
contain
two
amino
acid
glycosid
carbohydr
chain
free
group
exhibit
significantli
time
greater
inhibit
sarscov
vero
cell
cultur
howev
cytotox
increas
simultan
introduc
carbohydr
chain
viii
produc
increas
antisarscov
activ
compound
ii
deriv
inact
sarscov
suggest
carbohydr
part
signific
manifest
antisarscov
activ
antivir
activ
found
ii
carbenoxolon
disodium
salt
ii
acid
succin
x
certain
deriv
certain
dnaand
rnavirus
includ
compound
x
also
effect
treat
volunt
herpet
infect
due
compound
x
use
europ
mani
year
appear
histamin
h
receptor
antagonist
treat
stomach
duoden
ulcer
solut
x
also
inactiv
vesicular
stomatitu
viru
vitro
structureact
relationship
ii
latter
studi
hepat
b
viru
found
ii
activ
inhibitor
viru
antigen
compound
inhibit
hsv
thymidinekinas
mechan
antivir
activ
ii
deriv
yet
fulli
explain
found
compound
affect
one
sever
stage
cellular
process
control
viru
morphogenesi
uniqu
properti
new
mechan
action
hiv
licoric
glycosid
activ
even
earli
stage
viral
replic
cycl
prevent
adsorpt
viru
cell
propos
mechan
antihiv
effect
due
blockag
viru
adsorpt
cell
surfac
blockag
bond
format
glycoprotein
gp
viru
surfac
cd
receptor
confirm
inhibit
proteinkinas
c
enzym
respons
bind
particl
cellular
cd
receptor
greater
inhibit
activ
compound
upon
addit
cell
cultur
viru
adsorpt
argu
princip
antihiv
activ
triterpen
deriv
due
effect
earli
stage
viru
reproduct
cycl
preced
penetr
viru
cell
thu
studi
antihiv
activ
innocul
cultur
human
lymphocyt
cell
show
glycosid
block
effect
viru
reproduct
upon
addit
cell
suspens
simultan
viru
viru
adsorpt
shown
inhibit
hiv
rt
key
enzym
life
cycl
requir
earli
stage
cell
infect
high
concentr
concentr
mm
suppress
rt
activ
also
aglycon
ii
deriv
inhibit
rt
lower
concentr
act
noncompet
inhibitor
compound
also
inhibit
effect
product
cell
cultur
chronic
infect
model
earli
stage
viru
replic
cycl
capabl
ii
inhibit
rt
led
conclus
activ
triterpenoid
direct
earli
stage
hiv
life
cycl
mix
natur
ie
prevent
adsorpt
interact
viru
enzym
recombin
rt
character
glycyrrhizinbind
protein
furthermor
inhibit
select
phosphorylyt
activ
kinas
p
found
recombin
rt
function
effect
phosphat
acceptor
recombin
human
casein
kinas
ii
vitro
ii
high
concentr
mm
suppress
phosphoryl
enzym
result
suggest
antihiv
effect
deriv
ii
may
due
select
inhibit
rt
cellular
level
mediat
recombin
casein
kinas
ii
compound
also
show
dosedepend
inhibit
protein
kinas
infect
clonal
cell
also
shown
inhibit
gene
express
compound
also
direct
effect
protein
kinas
vesicular
stomatitu
virus
variou
phase
viru
cycl
chang
upon
reaction
hsv
virion
accompani
irrevers
inactiv
viru
particl
found
free
state
outsid
cell
compound
disrupt
irrevers
synthesi
viru
glycoprotein
nontox
dose
cell
infect
viru
cell
cultur
affect
cell
glycoprotein
rang
activ
concentr
howev
higher
dose
inhibit
also
synthesi
cellular
glycoprotein
compound
modifi
intracel
baltina
et
al
compound
carbenoxolon
suppress
strongli
glycoprotein
variou
cell
type
antivir
capabl
deriv
also
affect
abil
enhanc
product
ginterferon
tcell
test
volunt
show
iv
administr
dose
mgkg
increas
content
interferon
normal
killer
cell
plasma
stimul
effect
secret
induc
product
interferon
peripher
lymphocyt
note
deriv
ii
cycloxolon
x
exhibit
antivir
activ
inhibit
product
viru
particl
mainli
sever
damag
virion
progen
antihiv
effect
ii
also
due
select
inhibit
rt
casein
kinas
ii
cellular
level
furthermor
antivir
effect
ii
link
stimul
product
express
nosynthas
gene
macrophag
shown
experi
mice
compound
x
prostaglandin
show
synergist
inhibit
vaccinia
viru
reproduct
cell
obvious
effect
triterpenoid
prostaglandin
viru
reproduct
independ
enhanc
inhibit
vaccinia
viru
observ
coadministr
indic
compound
act
differ
stage
viru
replic
increas
suppress
viru
compound
ad
pharmaceut
prepar
treat
diseas
caus
retrovirus
compound
salt
propos
treat
aid
oral
parenter
administr
compound
use
pure
form
salt
organ
cholin
inorgan
ammonium
alkali
metal
base
prolong
treatment
asymptomat
hiv
carrier
glycyron
prepar
prevent
progress
diseas
patient
high
ratio
sever
valuabl
drug
base
develop
foreign
pharmaceut
firm
thu
snmc
prepar
stronger
neominophagen
co
contain
glycyrrhizin
cystein
glycin
physiolog
solut
use
sinc
iv
treatment
chronic
viral
hepatitis
b
c
liver
cirrhosi
good
result
treatment
chronic
hepat
patient
obtain
combin
snmc
prepar
interferon
combin
glycyrrhizin
interferon
effect
treatent
patient
interferonresist
form
hepat
c
glycyrrhizin
exhibit
synerget
antivir
activ
also
combin
interferon
hepat
viru
snmc
prepar
use
success
treat
patient
infect
simultan
hepat
c
hiv
virus
combin
glycyrrhizin
lamivudin
use
success
therapi
viral
hepatitis
b
e
includ
subact
tablet
glycyron
contain
glycyrrhizin
complex
lmethionin
glycin
altern
snmc
prepar
oral
administr
use
snmc
prepar
treat
hepatitis
publish
review
start
longterm
clinic
test
snmc
prepar
patient
asymptomat
hiv
carrier
aid
patient
high
ratio
conduct
clinic
improv
observ
half
patient
upon
iv
administr
prepar
phosphogliv
domest
prepar
approv
broad
medic
applic
hepatoprotector
develop
manufactur
v
n
orekhovich
institut
biomed
chemistri
prepar
contain
trisodium
salt
also
stabil
emulsifi
inhibit
prepar
replic
hepat
b
c
virus
posit
influenc
immun
interferon
statu
note
allow
use
treat
chronic
hepat
b
c
virus
patient
chronic
diffus
liver
diseas
due
metabol
disord
compound
salt
ammonium
potassium
sodium
use
prepar
extern
applic
treat
viral
diseas
skin
oral
caviti
nose
stomat
herp
eye
genitalia
vagina
organ
caus
combin
drug
antibiot
antivir
prepar
corticosteroid
etc
antivir
prepar
base
extern
topic
applic
spray
trade
name
epigen
intim
develop
prepar
design
prevent
therapi
viral
infect
sex
organ
caus
hsv
acut
primari
recidivist
viral
infect
membran
skin
mouth
nose
bodi
part
extern
treatment
shingl
caus
viru
varicella
zoster
sexual
relat
prevent
infect
sexual
transmit
diseas
epigen
intim
also
highli
effect
treatment
papilloma
viru
infect
caus
genit
condylomatosi
purifi
use
biolog
activ
addit
viucid
contain
addit
complex
amino
acid
vitamin
trace
element
prepar
pass
clincial
test
monoand
complex
therapi
hiv
infect
hepatitis
b
c
herpet
infect
cytomegaloviru
infect
flu
paraflu
adenoand
rotavirus
lead
clinic
world
includ
russia
use
pharmaceut
prepar
clinic
applic
deriv
also
review
thu
potenti
triterpen
compound
produc
licoric
signific
creat
antivir
virucid
prepar
battl
social
danger
viru
infect
compound
deriv
princip
candid
applic
system
therapi
prevent
hiv
infect
hepatitis
b
c
sar
cov
infect
herpet
infect
